BioAtla, Inc. (NASDAQ:BCAB) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lessened its stake in shares of BioAtla, Inc. (NASDAQ:BCAB) by 1.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 706,062 shares of the company’s stock after selling 9,133 shares during the period. Vontobel Holding Ltd. owned about 1.47% of BioAtla worth $1,737,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BCAB. Swiss National Bank boosted its position in shares of BioAtla by 17.8% in the 1st quarter. Swiss National Bank now owns 50,200 shares of the company’s stock valued at $251,000 after purchasing an additional 7,600 shares during the period. BlackRock Inc. lifted its stake in BioAtla by 0.5% during the first quarter. BlackRock Inc. now owns 1,594,238 shares of the company’s stock valued at $7,970,000 after buying an additional 8,344 shares in the last quarter. Ergoteles LLC acquired a new position in shares of BioAtla in the first quarter worth about $79,000. Prudential Financial Inc. purchased a new position in shares of BioAtla in the first quarter worth approximately $130,000. Finally, XTX Topco Ltd acquired a new stake in shares of BioAtla during the first quarter valued at approximately $91,000. 77.23% of the stock is owned by institutional investors.

BioAtla Stock Performance

BioAtla stock opened at $2.11 on Friday. The firm’s 50 day moving average price is $2.81 and its two-hundred day moving average price is $2.23. The firm has a market cap of $101.25 million, a PE ratio of -0.81 and a beta of 1.08. BioAtla, Inc. has a twelve month low of $1.24 and a twelve month high of $4.07.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Tuesday, March 26th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.12. Equities analysts anticipate that BioAtla, Inc. will post -1.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright decreased their price objective on shares of BioAtla from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 27th. JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of BioAtla in a research report on Thursday, March 28th.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.